Ethan Covey on Muck Rack

Ethan Covey

As seen in: Bandcamp Daily, People, Seven Days, The 405, Infectious Disease Special Edition, Pain Medicine News, Pharmacy Practice News, Field Mag, General Surgery News, Connecticut Cottages & Gardens and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ethan

Contact Ethan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Funding Freeze Has Caused Wide Disruptions in HIV Services

|
By Ethan Covey
| Infectious Disease Special Edition
Widespread disruptions in HIV care have occurred following the freeze of U.S. government foreign assistance funds, according to a survey of HIV clinics and programs that was presented at CROI 2026, in Denver (poster 1051). The rapid mid-2025 survey of HIV clinics and programs in 32 countries found widespread disruptions in HIV care after the funding freeze of U.S. government foreign assistance earlier that year.
Open in Who Shared Issue with article?

Lenacapavir Resistance Appears Rare, Supporting Durability of Capsid Inhibition

|
By Ethan Covey
| Infectious Disease Special Edition
A newly published study provides one of the most detailed analyses to date of resistance patterns associated with lenacapavir, a first-in-class HIV capsid inhibitor approved by the FDA for heavily treatment-experienced patients and for HIV pre-exposure prophylaxis (PrEP) (Sci Transl Med 2026;18[831]:eaea0947). Why Study Resistance Patterns in a New Drug?
Open in Who Shared Issue with article?

Remdesivir Criteria Save $500K+ And Preserve Clinical Outcomes

|
By Ethan Covey
| Pharmacy Practice News
Originally published by our sister publication Specialty Pharmacy Continuum A systemwide shift to more restrictive remdesivir (Veklury, Gilead Sciences) eligibility criteria led to a substantial reduction in drug use and associated costs—without worsening clinical outcomes—according to a retrospective analysis presented at the ASHP Midyear 2025 Clinical Meeting & Exhibition, in Las Vegas.
Open in Who Shared Issue with article?
See all 217 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Ethan

Contact Ethan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified